Avelumab in gastric cancer

Giandomenico Roviello, Alberto D'Angelo, Daniele Generali, Matteo Pittacolo, Monica Ganzinelli, Giandomenica Iezzi, Nicolò de Manzini, Navid Sobhani

Research output: Contribution to journalArticle

1 Citation (Scopus)
2 Downloads (Pure)

Abstract

Gastric cancer (GC) is the fifth most common malignancy and the third cause of cancer-related deaths worldwide. Currently, surgery and chemotherapy remain the main therapeutic options and the prognosis of the disease is still poor in the metastatic setting. Avelumab is a human IgG1 antibody directed against PD-L1 approved for Merkel cell carcinoma and urothelial carcinoma that could be useful also for the treatment of GC. This review describes the chemical structure, the pharmacologic properties and the current knowledge of the efficacy of avelumab in the treatment of GC from the data available on the first and later phase clinical trials. The ongoing studies testing this drug either alone or in combination with other drugs are also described.

Original languageEnglish
Pages (from-to)759-768
Number of pages10
JournalImmunotherapy
Volume11
Issue number9
Early online date6 May 2019
DOIs
Publication statusPublished - 16 May 2019

Keywords

  • avelumab
  • gastric cancer
  • immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Roviello, G., D'Angelo, A., Generali, D., Pittacolo, M., Ganzinelli, M., Iezzi, G., Manzini, N. D., & Sobhani, N. (2019). Avelumab in gastric cancer. Immunotherapy, 11(9), 759-768. https://doi.org/10.2217/imt-2019-0011